Neurovascular Intervention Devices Global Market – Forecast To 2027

Publishing Date : October, 2020
Report Code : HCMD0159
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Over the decade, due to the technological advancements with emerging and innovative technologies used under minimally invasive conditions has led to the rapid development of neurovascular interventions. As a result of rapid advances, there is the great expansion in the potential therapeutic application for neurovascular diseases.

Neurovascular Interventional devices are used to treat intracranial aneurysm, ischemic stroke, arteriovenous malformation, carotid stenosis and other diseases like intracranial stenosis, dural fistula. The Neurovascular Intervention Devices global market is expected to grow at a high single digit CAGR to reach $4,167.4 million by 2027. The market is primarily driven by the increase in incidence and prevalence of neurovascular diseases like intracranial aneurysm, stroke and arteriovenous malformations, increase in the aging population, technological advancement, acquisitions and favourable reimbursements and factors such as product recall, complications associated with implanted devices, lack of skilled and trained professionals, emerging alternatives such as stem cell therapies, radiation therapies and also stringent regulatory policies for the product approval due to classification of the neurovascular interventions as class II and III devices thereby hindering the growth of the market.

Neurovascular Intervention devices global market is segmented based on products, applications and geography. The products are segmented into artificial embolization devices, stents, thrombectomy devices and support devices. Among products, the artificial embolization devices segment accounted for the largest share in 2020 and is projected to grow at a low single digit CAGR from 2020 to 2027 due to technological advancements in coils & flow diverter, development of coils for dual application i.e. for intracranial aneurysm and arteriovenous malformation. Further, the artificial embolization devices are sub-segment into coils, liquid embolics, flow diverters, flow disruptors and others (embolic spheres and vascular plugs). The coil segment accounted for the largest share in 2020 due to the development of soft and smart coils.

As Neuroendovascular space has responded to a significant advance in the properties of coils such as pliability, detachment zone, coatings, lengths, and shapes hence, driving the coils market. The flow diverter segment is the fastest-growing segment and is projected to grow at a high single digit CAGR from 2020 to 2027 due to its advantages like the presence of effective embolic materials that penetrates small vessels, nature of self-expansion, cohesiveness and non-adherence when compared to glues. The coils are further classified into bare metal coils and coated coils. The bare metal coil segment accounted for the largest share in 2020 and the coated coil segment is the fastest-growing segment and is projected to grow at a low single digit CAGR from 2020 to 2027 due to increased compatibility, efficacy and cost.

The Stents are sub-segmented into intracranial stents and carotid stents. The carotid stents segment accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027, owing to the development of self-expanding stents and is used in patients who have high surgical risk and also the availability of different stent structures to tailor the procedures in a different subset of lesions in the brain. The intracranial stents are sub-segmented into stenosis stent and aneurysm coil stent. The aneurysm coil stents segment accounted for the largest share in 2020 and the stenosis stent segment is projected to grow at a high single digit CAGR from 2020 to 2027 due to increase in the intracranial aneurysm procedures. The thrombectomy devices are sub-segmented into stent retrievers and aspiration devices. The stent retriever segment accounted the largest share of in 2020 and is expected to grow at a low double digit CAGR from 2020 to 2027 due to product approvals and expansion in indication of treatment from 6 hrs to 24 hrs.

The global neurovascular intervention markets by applications are segmented into intracranial aneurysm, ischemic stroke, arteriovenous malformation and others. Among applications, the intracranial aneurysm segment accounted for the largest share in 2020 due to the increase in incidence and prevalence of intracranial aneurysm and increase in the aging population. The Ischemic stroke segment is fastest-growing segment during the forecasting period with a high single digit CAGR from 2020 to 2027 due to increase in product regulatory approvals of thrombectomy devices, increase in ischemic stroke patients which are in turn driven by the rise in population with smoking, alcohol consumption, hypertension and diabetes, technological advancement in stent retriever and aspiration devices which aids in local arrest of blood flow and removal of thrombus without fragmentation and theses devices can retrieve clots of large size.

The global neurovascular intervention global market by geography is segmented as North America (U.S. and others), Europe (Germany, U.K., France and Others), Asia-Pacific (Japan, China, India, and Others) and Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounted for the highest market share followed by Europe in 2020. Favourable reimbursement coverage, adoption of advanced minimally invasive procedures and increase in incidence and prevalence of neurovascular diseases are the driving neurovascular intervention devices market. The Asia-Pacific region is the fastest-growing region with a high single digit CAGR from 2020 to 2027. However, Asian countries especially India and China are the fastest-growing nations at a high single digit CAGR from 2020 to 2027 with its growing awareness of minimally invasive techniques, a gradual increase in the healthcare expenditure and increase in the aging population and reduction in the cost of neurovascular interventions.

The Neurovascular Intervention devices market is a consolidated, highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Some of the key players of the Neurovascular Intervention devices global market are Stryker Corporation (U.S.), Medtronic Plc (Ireland), Penumbra, Inc. (U.S.), Terumo Corporation (Micro Vention, Japan), Johnson & Johnson (U.S.), Balt Extrusion (France), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), Silk Road Medical Inc. (U.S.), Microport Scientific Corporation (China), and Acandis GmbH (Germany).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Others
  • Europe
  • Germany
  • U.K.
  • France
  • Others
  • Asia-Pacific 
  • Japan
  • China
  • India
  • Others
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East & Others
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT SCOPE
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCE
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASE IN INCIDENCE AND PREVALENCE OF NEUROVASCULAR DISEASES
        • 3.3.1.2     TECHNOLOGICAL ADVANCEMENTS IN MINIMALLY INVASIVE PRODUCTS
        • 3.3.1.3     FAVORABLE REIMBURSEMENT POLICIES
        • 3.3.1.4     INCREASE IN THE AGEING POPULATION
        • 3.3.1.5     ACQUISITIONS AND PARTNERSHIPS AS A PART OF THE GROWTH STRATEGY
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     ADVERSE EVENTS AND COMPLICATIONS WITH THE IMPLANTATIONS OF NEUROVASCULAR INTERVENTION DEVICES
        • 3.3.2.2     LACK OF SKILLED AND TRAINED PROFESSIONALS
        • 3.3.2.3     PRODUCT RECALLS
        • 3.3.2.4     STRINGENT REGULATORY POLICIES
        • 3.3.2.5     AVAILABILITY OF ALTERNATIVE PRODUCTS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 13485 MEDICAL DEVICES
        • 3.4.1.3     ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES
      • 3.4.2     THE U.S.
      • 3.4.3     CANADA
      • 3.4.4     EUROPE
      • 3.4.5     JAPAN
      • 3.4.6     CHINA
      • 3.4.7     INDIA
    • 3.5     REIMBURSEMENT SCENARIO
      • 3.5.1     REIMBURSEMENT TABLE
    • 3.6     FUNDING SCENARIO
    • 3.7     PATENT TRENDS
    • 3.8     TECHNOLOGICAL ADVANCEMENTS
      • 3.8.1     INTRODUCTION
      • 3.8.2     ADVANCEMENT IN THROMBECTOMY DEVICES
      • 3.8.3     EMBOLIZATION
      • 3.8.4     LIQUID EMBOLIZATION
      • 3.8.5     FLOW DIVERTER
      • 3.8.6     OTHER DEVICES
    • 3.9     PRODUCT APPROVALS
    • 3.10     PORTER’S FIVE FORCE ANALYSIS
      • 3.10.1     THREAT OF NEW ENTRANTS
      • 3.10.2     THREAT OF SUBSTITUTES
      • 3.10.3     RIVALRY AMONG EXISTING COMPETITORS
      • 3.10.4     BARGAINING POWER OF SUPPLIERS
      • 3.10.5     BARGAINING POWER OF BUYERS
    • 3.11     SUPPLY CHAIN ANALYSIS
    • 3.12     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.12.1     NEUROVASCULAR INTERVENTIONAL DEVICES GLOBAL MARKET SHARE ANALYSIS
      • 3.12.2     COILS GLOBAL MARKET SHARE ANALYSIS
      • 3.12.3     FLOW DIVERTERS GLOBAL MARKET SHARE ANALYSIS
      • 3.12.4     INTRACRANIAL STENT GLOBAL MARKET SHARE ANALYSIS
      • 3.12.5     CAROTID STENT GLOBAL MARKET SHARE ANALYSIS
      • 3.12.6     STENT RETRIEVER GLOBAL MARKET SHARE ANALYSIS
      • 3.12.7     ASPIRATION CATHETERS GLOBAL MARKET SHARE ANALYSIS
      • 3.12.8     LIQUID EMBOLICS GLOBAL MARKET SHARE ANALYSIS
    • 3.13     NEUROVASCULAR INTERVENTION DEVICES NUMBER OF UNITS BY REGION
      • 3.13.1     COILS NUMBER OF UNITS BY REGION
      • 3.13.2     LIQUID EMBOLICS NUMBER OF UNITS BY REGION
      • 3.13.3     STENT RETRIEVER NUMBER OF UNITS BY REGION
      • 3.13.4     ASPIRATION DEVICES NUMBER OF UNITS BY REGION
      • 3.13.5     INTRACRANIAL STENTS NUMBER OF UNITS BY REGION
      • 3.13.6     CAROTID STENT NUMBER OF UNITS BY REGION
    • 3.14     NEUROVASCULAR INTERVENTION DEVICES COMPANY COMPARISON TABLE BY CLASSIFICATION, PRODUCTS AND APPLICATIONS
    • 3.15     MARKET PENETRATION OF NEUROVASCULAR INTERVENTION DEVICES MARKET
  • 4     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     ARTIFICIAL EMBOLIZATION DEVICES
      • 4.2.1     COILS
        • 4.2.1.1     BARE METAL COILS
        • 4.2.1.2     COATED COILS
      • 4.2.2     LIQUID EMBOLICS
      • 4.2.3     FLOW DIVERTERS
      • 4.2.4     FLOW DISRUPTOR
      • 4.2.5     OTHERS
    • 4.3     STENTS
      • 4.3.1     INTRACRANIAL STENTS
        • 4.3.1.1     STENOSIS STENTS
        • 4.3.1.2     ANEURYSM COIL STENTS
      • 4.3.2     CAROTID STENTS
    • 4.4     THROMBECTOMY DEVICES
      • 4.4.1     STENT RETRIEVERS
      • 4.4.2     ASPIRATION DEVICES
    • 4.5     SUPPORT DEVICES
  • 5     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET, BY APPLICATION
    • 5.1     INTRODUCTION
    • 5.2     INTRACRANIAL ANEURYSM
    • 5.3     ISCHEMIC STROKE
    • 5.4     ARTERIOVENOUS MALFORMATION
    • 5.5     OTHER DISEASES
  • 6     REGIONAL ANALYSIS
    • 6.1     INTRODUCTION
    • 6.2     NORTH AMERICA
      • 6.2.1     U.S.
      • 6.2.2     REST OF NORTH AMERICA
    • 6.3     EUROPE
      • 6.3.1     GERMANY
      • 6.3.2     U.K.
      • 6.3.3     FRANCE
      • 6.3.4     REST OF EUROPE
    • 6.4     APAC
      • 6.4.1     JAPAN
      • 6.4.2     CHINA
      • 6.4.3     INDIA
      • 6.4.4     REST OF APAC
    • 6.5     REST OF THE WORLD
      • 6.5.1     BRAZIL
      • 6.5.2     REST OF LATIN AMERICA
      • 6.5.3     MIDDLE EAST AND OTHERS
  • 7     COMPETITIVE LANDSCAPE
    • 7.1     INTRODUCTION
    • 7.2     PRODUCT APPROVAL
    • 7.3     AGREEMENTS
    • 7.4     PRODUCT LAUNCH
    • 7.5     ACQUISITION
    • 7.6     OTHER DEVELOPMENTS
  • 8     MAJOR COMPANIES
    • 8.1     ABBOTT LABORATORIES
      • 8.1.1     OVERVIEW
      • 8.1.2     FINANCIALS
      • 8.1.3     PRODUCT PORTFOLIO
      • 8.1.4     KEY DEVELOPMENTS
      • 8.1.5     BUSINESS STRATEGY
      • 8.1.6     SWOT ANALYSIS
    • 8.2     BALT EXTRUSION
      • 8.2.1     OVERVIEW
      • 8.2.2     FINANCIALS
      • 8.2.3     PRODUCT PORTFOLIO
      • 8.2.4     KEY DEVELOPMENTS
      • 8.2.5     BUSINESS STRATEGY
      • 8.2.6     SWOT ANALYSIS
    • 8.3     BOSTON SCIENTIFIC CORPORATION
      • 8.3.1     OVERVIEW
      • 8.3.2     FINANCIALS
      • 8.3.3     PRODUCT PORTFOLIO
      • 8.3.4     KEY DEVELOPMENTS
      • 8.3.5     BUSINESS STRATEGY
      • 8.3.6     SWOT ANALYSIS
    • 8.4     JOHNSON & JOHNSON (CERENOVUS)
      • 8.4.1     OVERVIEW
      • 8.4.2     FINANCIALS
      • 8.4.3     PRODUCT PORTFOLIO
      • 8.4.4     KEY DEVELOPMENTS
      • 8.4.5     BUSINESS STRATEGY
      • 8.4.6     SWOT ANALYSIS
    • 8.5     MEDTRONIC PUBLIC LIMITED COMPANY
      • 8.5.1     OVERVIEW
      • 8.5.2     FINANCIALS
      • 8.5.3     PRODUCT PORTFOLIO
      • 8.5.4     KEY DEVELOPMENTS
      • 8.5.5     BUSINESS STRATEGY
      • 8.5.6     SWOT ANALYSIS
    • 8.6     MICROPORT SCIENTIFIC CORPORATION
      • 8.6.1     OVERVIEW
      • 8.6.2     FINANCIALS
      • 8.6.3     PRODUCT PORTFOLIO
      • 8.6.4     KEY DEVELOPMENTS
      • 8.6.5     BUSINESS STRATEGY
      • 8.6.6     SWOT ANALYSIS
    • 8.7     PENUMBRA, INC
      • 8.7.1     OVERVIEW
      • 8.7.2     FINANCIALS
      • 8.7.3     PRODUCT PORTFOLIO
      • 8.7.4     KEY DEVELOPMENTS
      • 8.7.5     BUSINESS STRATEGY
      • 8.7.6     SWOT ANALYSIS
    • 8.8     SILK ROAD MEDICAL, INC
      • 8.8.1     OVERVIEW
      • 8.8.2     FINANCIALS
      • 8.8.3     PRODUCT PORTFOLIO
      • 8.8.4     KEY DEVELOPMENTS
      • 8.8.5     BUSINESS STRATEGY
      • 8.8.6     SWOT ANALYSIS
    • 8.9     STRYKER CORPORATION
      • 8.9.1     OVERVIEW
      • 8.9.2     FINANCIALS
      • 8.9.3     PRODUCT PORTFOLIO
      • 8.9.4     KEY DEVELOPMENTS
      • 8.9.5     BUSINESS STRATEGY
      • 8.9.6     SWOT ANALYSIS
    • 8.10     TERUMO CORPORATION
      • 8.10.1     OVERVIEW
      • 8.10.2     FINANCIALS
      • 8.10.3     PRODUCT PORTFOLIO
      • 8.10.4     KEY DEVELOPMENTS
      • 8.10.5     BUSINESS STRATEGY
      • 8.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 2     COILS NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 3     LIQUID EMBOLICS NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 4     STENT RETRIEVER NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 5     ASPIRATION DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 6     INTRACRANIAL STENTS NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 7     CAROTID STENT NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
      • TABLE 8     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 9     ARTIFICIAL EMBOLIZATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 10     ARTIFICIAL EMBOLIZATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 11     COILS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 12     COILS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 13     BARE METAL COILS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 14     COATED COILS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 15     LIQUID EMBOLICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 16     FLOW DIVERTERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 17     FLOW DISRUPTOR GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 18     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 19     STENTS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 20     STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 21     INTRACRANIAL STENTS GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 22     INTRACRANIAL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 23     STENOSIS STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 24     ANEURYSM COIL STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 25     CAROTID STENTS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 26     THROMBECTOMY DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 27     THROMBECTOMY DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 28     STENT RETRIEVERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 29     ASPIRATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 30     SUPPORT DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 31     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 32     INTRACRANIAL ANEURYSM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 33     ISCHEMIC STROKE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 34     ARTERIOVENOUS MALFORMATION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 35     OTHER DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 36     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 37     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 38     NORTH AMERICA ARTIFICIAL EMBOLIZATION DEVICES MARKET, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 39     NORTH AMERICA COILS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 40     NORTH AMERICA STENTS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 41     NORTH AMERICA INTRACRANIAL STENTS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 42     NORTH AMERICA THROMBECTOMY DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 43     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 44     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 45     EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 46     EUROPE ARTIFICIAL EMBOLIZATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 47     EUROPE COILS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 48     EUROPE STENTS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 49     EUROPE INTRACRANIAL STENTS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 50     EUROPE THROMBECTOMY DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 51     EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 52     EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 53     APAC NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 54     APAC ARTIFICIAL EMBOLIZATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 55     APAC COILS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 56     APAC STENTS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 57     APAC INTRACRANIAL STENTS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 58     APAC THROMBECTOMY DEVICE MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 59     APAC NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 60     APAC NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 61     ROW NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 62     ROW ARTIFICIAL EMBOLIZATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 63     ROW COILS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 64     ROW STENTS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 65     ROW INTRACRANIAL STENTS MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 66     ROW THROMBECTOMY DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
      • TABLE 67     ROW NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 68     ROW NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
      • TABLE 69     KEY DEVELOPMENTS (2018 –2020)
      • TABLE 70     PRODUCT APPROVAL
      • TABLE 71     AGREEMENTS
      • TABLE 72     PRODUCT LAUNCH
      • TABLE 73     ACQUISITION
      • TABLE 74     OTHER DEVELOPMENTS
      • TABLE 75     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 76     ABBOTT LABORATORIES: TOTAL REVENUE BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 77     ABBOTT LABORATORIES: MEDICAL DEVICES REVENUE BY SUB-SEGMENTS, (2018-2020) ($MN)
      • TABLE 78     ABBOTT LABORATORIES: TOTAL REVENUE BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 79     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 80     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 81     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 82     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2018 -2020) ($MN)
      • TABLE 83     JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 84     JOHNSON & JOHNSON: MEDICAL DEVICE REVENUE, BY SUB-SEGMENTS, (2018-2020) ($MN)
      • TABLE 85     JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 86     MEDTRONIC PLC: TOTAL REVENUE AND OPERATING EXPENSES (2019-2021) ($MN)
      • TABLE 87     MEDTRONIC PLC: TOTAL REVENUE, BY SEGMENT, (2019-2021) ($MN)
      • TABLE 88     MEDTRONIC PLC: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
      • TABLE 89     MICROPORT SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 90     MICROPORT SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 91     MICROPORT SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 92     PENUMBRA, INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 93     PENUMBRA, INC: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 94     PENUMBRA, INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 95     SILK ROAD MEDICAL INC: TOTAL REVENUE AND OPERATING EXPENSES (2018 -2020) ($MN)
      • TABLE 96     STRYKER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 97     STRYKER CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 98     STRYKER CORPORATION: NEUROTECHNOLOGY AND SPINE REVENUE, BY SUB-SEGMENT, (2018-2020) ($MN)
      • TABLE 99     STRYKER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 100     TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 101     TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN)
      • TABLE 102     TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET
      • FIGURE 3     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2015–2019)
      • FIGURE 9     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 10     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 12     COILS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 13     FLOW DIVERTERS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 14     INTRACRANIAL STENT GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 15     CAROTID STENT GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 16     STENT RETRIEVER MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 17     ASPIRATION CATHETERS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 18     LIQUID EMBOLICS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 19     COIL NUMBER OF UNITS, BY REGION (2020 V/S 2027) (NO’S)
      • FIGURE 20     LIQUID EMBOLICS NUMBER OF UNITS, BY REGION (2020 V/S2027) (NO’S)
      • FIGURE 21     STENT RETREIVER NUMBER OF UNITS, BY REGION (2020 V/S 2027) (NO’S)
      • FIGURE 22     ASPIRATION DEVICES NUMBER OF UNITS, BY REGION (2020 V/S 2027) (NO’S)
      • FIGURE 23     INTRACRANIAL STENTS NUMBER OF UNITS, BY REGION (2020 V/S 2027) (NO’S)
      • FIGURE 24     CAROTID STENT NUMBER OF UNITS, BY REGION (2020 V/S 2027) (NO’S)
      • FIGURE 25     U.S. NEUROVASCULAR INTERVENTION DEVICES MARKET PENETRATION, BY APPLICATION (2020) (%)
      • FIGURE 26     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
      • FIGURE 27     ARTIFICIAL EMBOLIZATION DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 28     COILS GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 29     BARE METAL COILS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 30     FLOW DISRUPTOR GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 31     STENTS GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 32     INTRACRANIAL STENTS GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 33     INTRACRANIAL STENTS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 34     STENOSIS STENTS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 35     ANEURYSM COIL STENTS GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
      • FIGURE 36     THROMBECTOMY DEVICES GLOBAL MARKET SHARE, BY TYPE (2020 V/S 2027) (%)
      • FIGURE 37     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 38     NEUROVASCULAR INTERVENTION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN), CAGR (%)
      • FIGURE 39     NORTH AMERICA ARTFICIAL EMBOLIZATION DEVICES MARKET SHARE, BY PRODUCT TYPE, (2020 VS 2027) (%)
      • FIGURE 40     NORTH AMERICA COILS MARKET SHARE, BY PRODUCT TYPE, (2020 VS 2027) (%)
      • FIGURE 41     NORTH AMERICA STENTS MARKET SHARE, BY PRODUCT TYPE, (2020 VS 2027) (%)
      • FIGURE 42     NORTH AMERICA INTRACRANIAL STENTS MARKET SHARE, BY PRODUCT TYPE, (2020 VS 2027) (%)
      • FIGURE 43     NORTH AMERICA THROMBECTOMY DEVICES MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 44     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY PRODUCT & APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 45     NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 46     U.S. NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 VS 2027) ($MN)
      • FIGURE 47     REST OF NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 48     EUROPE ARTIFICIAL EMBOLIZATION DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 VS 2027) (%)
      • FIGURE 49     EUROPE COILS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 50     EUROPE STENTS MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 51     EUROPE INTRACRANIAL STENTS MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
      • FIGURE 52     EUROPE THROMBECTOMY DEVICES MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 53     EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY PRODUCT & APPLICATION, (2020 VS 2027) (%)
      • FIGURE 54     EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 55     GERMANY NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 56     U.K. NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 57     FRANCE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 58     REST OF EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 VS 2027) ($MN)
      • FIGURE 59     APAC ARTIFICIAL EMBOLIZATION MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 60     APAC COILS MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 61     APAC STENTS MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 62     APAC INTRACRANIAL STENTS MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 63     APAC THROMBECTOMY DEVICES MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 64     APAC NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY PRODUCT & APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 65     APAC NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 66     JAPAN NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 67     CHINA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 68     INDIA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 69     REST OF APAC COUNTRIES NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 70     ROW ARTIFICIAL EMBOLIZATION DEVICES MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 71     ROW COILS MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 72     ROW STENTS MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 73     ROW INTRACRANIAL STENTS MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 74     ROW THROMBECTOMY DEVICES MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
      • FIGURE 75     ROW NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY PRODUCT & APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 76     ROW NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 77     BRAZIL NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 78     REST OF LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 79     MIDDLE EAST AND OTHERS NEUROVASCULAR INTERVENTION DEVICES MARKET REVENUE, BY PRODUCT & APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 80     SWOT: ABBOTT LABORATORIES
      • FIGURE 81     SWOT: BALT EXTRUSION
      • FIGURE 82     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 83     SWOT: JOHNSON & JOHNSON
      • FIGURE 84     SWOT: MEDTRONIC PLC
      • FIGURE 85     SWOT: MICROPORT SCIENTIFIC CORPORATION
      • FIGURE 86     SWOT: PENUMBRA, INC
      • FIGURE 87     SWOT: SILK ROAD MEDICAL, INC
      • FIGURE 88     SWOT: STRYKER CORPORATION
      • FIGURE 89     SWOT: TERUMO CORPORATION

      COMPANIES MENTIONED IN THE REPORT

      • 1     Abbott Laboratories
      • 2     Acandis GmbH
      • 3     Achieva Medical
      • 4     Allium Medical
      • 5     Anaconda Biomed SL
      • 6     Artio Medical Inc.
      • 7     Asahi Intecc Co., Ltd
      • 8     Balt Extrusion
      • 9     Balton Sp. z o.o.
      • 10     Biomerics
      • 11     Biomodex
      • 12     Boston Scientific Corporation
      • 13     Cardiatis
      • 14     Cardinal Health, Inc
      • 15     Ceretrieve Ltd
      • 16     CereVasc, Inc.
      • 17     Cerus Endovascular
      • 18     Contego Medical, LLC
      • 19     Cook Medical
      • 20     Creganna Medical
      • 21     eLum Technologies, Inc.
      • 22     Evasc Medical Systems
      • 23     Fluidx Medical Technology
      • 24     Imperative Care Inc
      • 25     InspireMD
      • 26     Instylla Inc
      • 27     Integer Holdings Corporation
      • 28     Jiushi Shenkang Medical Technology
      • 29     Johnson & Johnson (Cerenovus)
      • 30     Kaneka Corporation
      • 31     Kaneka Pharma America LLC
      • 32     Medtronic Plc
      • 33     Merlin MD Pte. Ltd.
      • 34     Microport Scientific Corporation
      • 35     MIVI Neuroscience
      • 36     Monarch Biosciences, Inc. (Monarch Bio)
      • 37     Natec Medical Ltd
      • 38     NeuroVasc Technologies, Inc.
      • 39     NexGen Medical Systems
      • 40     Optimed
      • 41     Oxford Endovascular Ltd
      • 42     Penumbra Inc.
      • 43     Perflow Medical Ltd
      • 44     Phenox GmbH
      • 45     Rapid Medical Ltd
      • 46     Rist Neurovascular
      • 47     Shape Memory Medical Inc. 
      • 48     Siemens Healthineers
      • 49     Silk Road Medical Inc.
      • 50     Spartan Micro, Inc.
      • 51     Stryker Corporation
      • 52     Terumo (Microvention)
      • 53     Varian Medical Systems
      • 54     Vention
      • 55     Vesalio
      • 56     W. L. Gore & Associates.
      • 57     Wallaby Medical